<div id="readability-page-1"><p>In a report released today, Patrick Trucchio from H.C. Wainwright reiterated a Buy rating on Helus Pharma, with a price target of <span id="expert-recommendation-target">$95.00</span>.</p><h3>Claim 55% Off TipRanks</h3><ul><li>Unlock  hedge fund-level data  and  powerful investing tools  for smarter, sharper decisions  </li><li> Discover top-performing stock ideas and upgrade to a portfolio of market leaders with  Smart Investor Picks  </li></ul> <p>According to TipRanks, Trucchio is a 5-star analyst with an average return of <span>27.2%</span> and a 52.24% success rate. Trucchio covers the Healthcare sector, focusing on stocks such as Atai Beckley N.V., Definium Therapeutics, and Immunocore Holdings.</p> <p>Currently, the analyst consensus on Helus Pharma is a Strong Buy with an average price target of $41.17.</p></div>

HELP

SBIO

<p>H.C. Wainwright analyst Patrick Trucchio has maintained a Buy rating on Helus Pharma (HELP) with a price target of $95.00. Trucchio, a 5-star analyst with a 27.2% average return, reports that the consensus on Helus Pharma is a Strong Buy, with an average price target of $41.17. He also covers other healthcare stocks like Atai Beckley N.V. and Immunocore Holdings.</p>

Tip Ranks

Cybin

ALPS Medical Breakthrough

iShares US Pharma

Invesco Biotechnology & Genome ETF

Health Care Select Sector SPDR

Ark Genomic Revolution ETF

iShares Biotechnology ETF

Proshares Ultra Nasdaq Biotech

VG Health

First Trust NYSE Arca Biotech Index Fd

Direxion S&P Biotech Bull 3X

SPDR S&P Biotech

iShares Global Healthcare

VanEck Biotech ETF

AtaiBeckley

Definium Therapeutics

Immunocore

H.C. Wainwright Keeps Their Buy Rating on Helus Pharma (HELP)